Alvesco 160mcg is a brand-name prescription medication containing the active ingredient ciclesonide [1]. It is a corticosteroid used for the maintenance treatment of asthma in adults and children 12 years of age and older [1].
How does Alvesco 160mcg work for asthma?
Alvesco 160mcg, with its active ingredient ciclesonide, functions as an inhaled corticosteroid (ICS). It works by reducing inflammation in the airways of the lungs [2]. By suppressing this inflammation, Alvesco helps to prevent the symptoms of asthma, such as wheezing, shortness of breath, chest tightness, and coughing, from occurring [1]. It is a controller medication, meaning it is taken daily to manage the underlying inflammation, rather than a rescue inhaler used for immediate symptom relief [2].
What is ciclesonide and how is it different?
Ciclesonide is a corticosteroid that is administered via inhalation. Once inhaled, it is converted into its active form, desisobutyryl-ciclesonide, specifically within the lung tissue [2]. This localized activation is a key characteristic, as it allows the drug to exert its anti-inflammatory effects directly in the airways while minimizing systemic exposure and potential side effects [2][3]. This targeted action is a distinguishing feature compared to some other inhaled corticosteroids.
When does the patent for Alvesco expire?
The patent expiration dates for Alvesco (ciclesonide) can be complex, involving multiple patents covering the composition of matter, formulation, and methods of use [4]. According to DrugPatentWatch.com, the patent situation for ciclesonide is subject to change and may involve various patent families [4]. To get the most current and detailed information on patent expiry dates, users can consult resources like DrugPatentWatch.com [4].
Can generic versions of Alvesco be sold before patents expire?
Generally, generic versions of a drug cannot be marketed until the relevant patents and any associated market exclusivities have expired [5]. This is to protect the intellectual property rights of the innovator company. However, legal challenges to patents can sometimes lead to earlier generic entry. Information on specific generic approvals and potential launch dates is often tracked by pharmaceutical intelligence services [4].
What are the potential side effects of Alvesco 160mcg?
As with any medication, Alvesco 160mcg can cause side effects. Common side effects may include headache, nasopharyngitis (common cold symptoms), and upper respiratory tract infections [1]. Some individuals might also experience throat irritation or hoarseness [2]. It is important for patients to discuss any concerns about side effects with their healthcare provider.
Who makes Alvesco and what are its competitors?
Alvesco is manufactured by Covis Pharma [1]. It competes in the market of inhaled corticosteroids for asthma treatment. Other commonly prescribed ICS medications include fluticasone propionate (e.g., Flovent), budesonide (e.g., Pulmicort), and mometasone furoate (e.g., Asmanex) [6]. These medications also work to reduce airway inflammation in asthma patients, though they may have different formulations and delivery devices.
How does Alvesco compare to other inhaled corticosteroids?
Alvesco (ciclesonide) is an inhaled corticosteroid that, like other ICS, reduces airway inflammation to control asthma symptoms. Its formulation as a dry powder inhaler delivers the medication directly to the lungs. Ciclesonide's characteristic of being a pro-drug, activated within the lungs, aims to enhance local efficacy while potentially reducing systemic absorption compared to some other ICS [2][3]. Clinical studies have evaluated its efficacy and safety profile in comparison to other ICS medications.
What are the risks of using inhaled corticosteroids like Alvesco?
While generally safe and effective for asthma management, inhaled corticosteroids like Alvesco carry potential risks, although these are often dose-dependent and more commonly associated with higher systemic exposure. Risks can include oral candidiasis (thrush) in the mouth or throat, hoarseness, and increased susceptibility to infections due to immunosuppression [7]. Long-term, high-dose use of ICS can also, in rare cases, be associated with effects on bone mineral density and growth velocity in children, though these are less common with typical therapeutic doses [7].
What clinical data supports the use of Alvesco 160mcg?
Clinical trials have demonstrated the efficacy of ciclesonide in improving lung function and reducing asthma exacerbations in adults and adolescents [2]. Studies have compared ciclesonide to placebo and other active comparator ICS medications to establish its therapeutic profile. The data supports its role as a maintenance treatment for persistent asthma [2].
How is Alvesco administered?
Alvesco is delivered using a dry powder inhaler device [1]. Patients inhale the medication deeply from the inhaler. Proper technique is crucial for ensuring the medication reaches the lungs effectively. Healthcare providers typically demonstrate the correct way to use the inhaler and advise patients on its regular use as prescribed [1].
What is the typical dosage for Alvesco 160mcg?
The recommended dosage for Alvesco 160mcg for adults and children 12 years of age and older is one inhalation taken twice daily [1]. The specific dosage and frequency can be adjusted by a healthcare professional based on the individual's asthma severity and response to treatment.
Where can I find more information about Alvesco patents?
For detailed and up-to-date information regarding patents for Alvesco and its active ingredient, ciclesonide, resources such as DrugPatentWatch.com are valuable [4]. These platforms track patent filings, approvals, and expiration dates, providing a comprehensive view of the intellectual property landscape surrounding pharmaceutical products.
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022171s004lbl.pdf
[2] https://www.alvesho.com/how-alvesco-works
[3] https://www.drugbank.ca/drugs/DB00602
[4] https://drugpatentwatch.com/
[5] https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas-generics/patent-terms-and-generic-drug-exclusivity
[6] https://www.ncbi.nlm.nih.gov/books/NBK557698/
[7] https://www.nhs.uk/conditions/asthma/treatment/inhalers/